Electrostatic interactions influence diazabicyclooctane inhibitor potency against OXA-48-like β-lactamases

Joseph F. Hoff, Kirsty E. Goudar, Karina Calvopiña, Michael Beer, Philip Hinchliffe, John M. Shaw, Catherine L. Tooke, Yuiko Takebayashi, Andrew F. Cadzow, Nicholas J. Harmer, Adrian J. Mulholland, Christopher J. Schofield, James Spencer*

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

Abstract

Carbapenemases, β-lactamases hydrolysing carbapenem antibiotics, challenge the treatment of multi-drug resistant bacteria. The OXA-48 carbapenemase is widely disseminated in Enterobacterales, necessitating new treatments for producer strains. Diazabicyclooctane (DBO) inhibitors, including avibactam and nacubactam, act on a wide range of enzymes to overcome β-lactamase-mediated resistance. Here we describe investigations on how avibactam and nacubactam inhibit OXA-48 and two variants, OXA-163 and OXA-405, with deletions in the β5–β6 loop neighbouring the active site that modify activity towards different β-lactam classes. Nacubactam is ∼80-fold less potent than avibactam towards OXA-48, but this difference reduces in OXA-163 and OXA-405. Crystal structures and molecular dynamics simulations reveal electrostatic repulsion between Arg214 on the OXA-48 β5–β6 active-site loop and nacubactam, but not avibactam; effects absent from simulations of OXA-163 and OXA-405, which lack Arg214. Crystallographic and mass spectrometry data demonstrate that all three enzymes support desulfation of the bound DBOs. The results indicate that interactions with Arg214 affect DBO potency, suggesting that sequence variation in OXA-48-like β-lactamases affects reactivity towards inhibitors as well as β-lactam substrates.
Original languageEnglish
Number of pages15
JournalRSC Medicinal Chemistry
Early online date8 Aug 2025
DOIs
Publication statusE-pub ahead of print - 8 Aug 2025

Bibliographical note

Publisher Copyright:
© 2025 RSC.

Fingerprint

Dive into the research topics of 'Electrostatic interactions influence diazabicyclooctane inhibitor potency against OXA-48-like β-lactamases'. Together they form a unique fingerprint.

Cite this